Higher Mortality in Patients With Diffuse Large B-cell Lymphoma Pre-Existing Arterial Hypertension-Real World Data of
Sebastian Szmit1, Monika Długosz-Danecka2, Joanna Drozd-Sokołowska3
1Department of Cardio-Oncology, Chair of Hematology and Transfusion Medicine, Centre of Postgraduate Medical Education, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Insights
Arterial hypertension (AH) significantly predicts premature cardiovascular mortality in diffuse large B-cell lymphoma (DLBCL) patients, independent of age. This highlights AH as a key factor for surveillance in cardio-oncology.
Area of Science:
- Cardio-oncology
- Hematology
- Cardiovascular Medicine
Background:
- Arterial hypertension (AH) is a recognized risk factor in cardio-oncology.
- The prognostic significance of AH in diffuse large B-cell lymphoma (DLBCL) requires further long-term evaluation.
Purpose of the Study:
- To assess the long-term prognostic value of pre-existing arterial hypertension (AH) in patients with diffuse large B-cell lymphoma (DLBCL).
Main Methods:
- Analysis of data from the Polish Lymphoma Research Group on DLBCL patients treated with first-line rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.
- Exclusion of patients with other cardiovascular comorbidities or premature chemotherapy discontinuation due to toxicity.
Main Results:
- Pre-existing AH was found in 28% of DLBCL patients and was associated with significantly shorter overall survival.
- Cardiovascular deaths were markedly higher in patients with AH (38.5% vs 3.6%).
- Multivariate analysis identified AH as an independent predictor of all-cause and cardiovascular mortality.
Conclusions:
- Arterial hypertension is a significant, age-independent predictor of premature cardiovascular mortality in DLBCL patients.
- The strong predictive role of AH suggests its utility in guiding surveillance strategies within cardio-oncology clinics.
Background:
Arterial hypertension is mentioned as a risk factor in cardio-oncology. This study aimed to assess the long-term prognostic value of arterial hypertension (AH) in diffuse large B-cell lymphoma (DLBCL).
Methods:
We analysed data collected by the Polish Lymphoma Research Group for the evaluation of the outcomes associated with the use of first-line rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone therapy in patients with DLBCL with coexisting AH. Patients with other cardiovascular comorbidities or premature chemotherapy discontinuation due to cardiovascular toxicity were excluded.
Results:
Pre-existing AH was diagnosed in 65 of 232 patients with DLBCL (28%) included in the study, and was associated with significantly shorter overall survival values (p<0.00001). The rates of DLBCL recurrence, administration of second-, third-, or fourth-line chemotherapy, and lymphoma-related deaths were similar in patients with and those without AH. Cardiovascular deaths were significantly more frequently observed in patients with pre-existing AH (38.5% vs 3.6%, p<0.0001). In the univariate analysis, AH (p=0.000001), older age (p<0.000001), and diabetes (p=0.0065) were identified as significant predictors of all-cause mortality; however, cardiovascular mortality was associated with AH (p<0.000001), older age (p=0.000008), and dyslipidaemia (p=0.03). Multivariate analysis revealed AH as an age-independent significant predictor of all-cause (p=0.00045) and cardiovascular mortality (p<0.000001).
Conclusion:
In the long-term follow-up of patients with DLBCL, the role of AH, as an important age-independent predictor of premature cardiovascular mortality, was so strong that it may have value for use in close surveillance in cardio-oncology clinics.
Related Concept Videos
Pre-Procedural Guidelines for Assessing Blood Pressure
Factors affecting Blood pressure
Physiological Factors:
Hypertension and Regulation of Blood Pressure
Disorders of the Autonomic Nervous System
Raynaud's disease, also known as Raynaud's...
Special considerations while measuring blood pressure
Monitoring Both Arms:
Monitoring BP in both arms during the initial assessment is advisable, as the systolic value may differ by five to ten mm Hg between arms. For subsequent BP assessments, use the arm with the higher reading.
Antihypertensive Drugs: Angiotensin II Receptor Blockers


